BeStock  
Stocks › Biotechnology › SLBT

SL Science SLBT

US equityMarket cap rank #3713Biotechnology
$0.55 −$0.03 (-5.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $0.55 0.00%
Open$0.57
Prev close$0.58
Day range$0.51 – $0.57
Volume28.6K
Market cap$308.42M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: ANNUAL, ended Dec 2025

Revenue$2.20M-34.7% YoY
Operating profit-$3.84M-220.8% YoY
Net profit-$3.82M-220.6% YoY
Diluted EPS-$0.01-220.7% YoY

Annual revenue

$879.0KFY23$3.4MFY24$2.2MFY25

Profitability & balance sheet

Gross margin38.4%
Operating margin-178.8%
Net margin-178.4%
Return on equity-74.9%
Return on assets-59.6%
Return on invested capital-72.4%
Current ratio4.44
Liabilities / assets21.8%
Cash & investments$8.31M
Total debt$0.00
Net cash (debt)$8.31M

Balance sheet

Line item 2026 Q2 2025 ANNUAL 2025 Q4 2025 Q2 2024 ANNUAL
Total Liabilities $1.94M $533,277.00 $533,277.00 $1.06M $204,899.00
Total Current Liabilities $1.94M $468,535.00 $468,535.00 $910,357.00 $69,198.00
Payables $1.60M – – $529,248.00 –
-Due to Related Parties Current $1.60M – – $491,429.00 –
Current Accrued Expenses $197,890.00 $313,037.00 $313,037.00 $212,729.00 $65,823.00
Other Current Liabilities $4,960.00 $6,835.00 $6,835.00 $13,456.00 $3,375.00
Total Non-Current Liabilities $0.00 $64,742.00 $64,742.00 $150,745.00 $135,701.00
Long Term Debt and Capital Lease Obligation $0.00 $64,742.00 $64,742.00 $150,745.00 $0.00
-Long Term Capital Lease Obligation $0.00 $64,742.00 $64,742.00 $150,745.00 $0.00
Total Equity $6.97M $2.28M $2.28M $4.73M $5.73M
Stockholders' Equity $6.97M $2.28M $2.28M $4.73M $5.73M
Non-Current Deferred Assets $0.00 $929,137.00 $929,137.00 $664,373.00 $50,000.00
-Accumulated Depreciation -$184,055.00 -$101,661.00 -$101,661.00 -$17,207.00 -$9,489.00
-Gross PPE $480,894.00 $562,879.00 $562,879.00 $684,232.00 $36,263.00
Short-Term Debt and Capital Lease Obligation $137,598.00 $148,663.00 $148,663.00 $154,924.00 –
Total Assets $8.91M $2.82M $2.82M $5.79M $5.93M
Total Current Assets $8.61M $1.43M $1.43M $4.46M $5.86M
Cash and Cash Equivalents & Short-Term Investments $8.31M $1.26M $1.26M $3.37M $3.68M
-Cash and Cash Equivalents $8.31M $1.26M $1.26M $3.37M $3.68M
Receivables $164,285.00 $129,699.00 $129,699.00 $119,712.00 $265,282.00
-Taxes Receivable $164,285.00 $129,413.00 $129,413.00 $119,712.00 $130,558.00
Prepaid Assets $70,055.00 $38,510.00 $38,510.00 $72,421.00 $92,599.00
Inventory $73,267.00 $0.00 $0.00 $722,755.00 $1.36M
Total Non-Current Assets $296,839.00 $1.39M $1.39M $1.33M $76,774.00
Net PPE $296,839.00 $461,218.00 $461,218.00 $667,025.00 $26,774.00
Capital Stock $5,616.00 $367,500.00 $367,500.00 $367,500.00 $367,500.00
-Current Capital Lease Obligation $137,598.00 $148,663.00 $148,663.00 $154,924.00 $0.00
-Preferred Stock $8.00 – – – –
Additional Paid-In Capital $14.16M $6.93M $6.93M $6.93M $6.80M
Retained Earnings -$7.65M -$5.48M -$5.48M -$3.27M -$1.66M
Gains/Losses Not Affecting Retained Earnings $453,764.00 $469,437.00 $469,437.00 $698,281.00 $228,466.00
-Common Stock $5,608.00 $367,500.00 $367,500.00 $367,500.00 $367,500.00
Non-Current Deferred Liabilities – $0.00 $0.00 $0.00 $135,701.00
Restricted Cash – $0.00 $0.00 $172,000.00 $457,500.00
-Other Receivables – $286.00 $286.00 – $134,724.00
-Total Tax Payable – – – $3,610.00 –
-Other Payable – – – $34,209.00 –

Cash flow

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL
Free Cash Flow -$2.23M $272,188.00 -$2.64M
Effect of Exchange Rate Changes $229,708.00 $228,655.00 -$7,163.00
Beginning Cash Balance $4.14M $439,354.00 $222,867.00
Financing Cash Flow -$879,137.00 $3.07M $2.86M
Net Cash Flow from Continuing Investing Activities -$319,685.00 $123,283.00 -$182,984.00
Net Intangibles Purchase and Sale $0.00 $3,448.00 $0.00
Net PPE Purchase and Sale -$319,685.00 $119,835.00 -$182,984.00
Net Cash Flow from Continuing Financing Activities -$879,137.00 $3.07M $2.86M
Net Common Stock Issuance $0.00 $7.24M $0.00
Net Other Financing Charges -$879,137.00 -$4.17M $2.86M
Ending Cash Balance $1.26M $4.14M $439,354.00
Net Change in Cash -$3.11M $3.47M $223,650.00
Net cash flow from investing -$319,685.00 $123,283.00 -$182,984.00
Net cash flow from continuing operations -$1.91M $280,158.00 -$2.45M
Other Non-Cash Items $155,694.00 $165,421.00 $173,173.00
Net Income from Continuing Operations -$3.82M -$1.19M $399,035.00
Depreciation & Depletion & Amortization $93,685.00 $47,247.00 $37,191.00
Operating Cash Flow -$1.91M $280,158.00 -$2.45M
Change in Working Capital $1.66M $1.27M -$3.06M
-Change in Receivables $0.00 $25,827.00 -$26,628.00
-Change in Inventory $1.35M $187,380.00 -$1.49M
-Change in Prepaid Assets $207,273.00 $1.12M -$1.53M
-Change in Payables and Accrued Expense $246,726.00 $38,620.00 $25,190.00
-Change in Other Current Liabilities -$137,455.00 -$166,609.00 -$171,948.00
-Change In Other Working Capital -$6,252.00 $57,488.00 $133,823.00
Gain/Loss from Continuing Operations – -$6,250.00 –

Income statement

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL
Basic EPS -$0.01 -$0.00 $0.00
Operating Profit -$3.84M -$1.20M $96,828.00
Research & Development $2.07M $2.02M $0.00
-General & Admin Expense $2.54M $1.11M $606,924.00
-Selling & Marketing Expense $0.00 $1,195.00 $34,256.00
Selling and Admin Expenses $2.54M $1.11M $641,180.00
Operating Expense $4.61M $3.13M $641,180.00
Gross Profit $775,062.00 $1.93M $738,008.00
Cost of Revenue $1.42M $1.43M $140,963.00
Total Operating Revenue $2.20M $3.36M $878,971.00
Net Non-Operating Interest Income (Expense) $40,302.00 $45,304.00 $1,612.00
Non-Operating Interest Income $40,302.00 $45,304.00 $1,612.00
Diluted EPS -$0.01 -$0.00 $0.00
Net Income to Common Stockholders -$3.82M -$1.19M $399,035.00
Net Income to Parent Company -$3.82M -$1.19M $399,035.00
Profit from Continuing Operations -$3.82M -$1.19M $399,035.00
Net Profit -$3.82M -$1.19M $399,035.00
Tax -$4.00 $57,635.00 $133,835.00
Pretax Profit -$3.82M -$1.13M $532,870.00
Other Non-Operating Income (Expenses) -$22,636.00 $17,109.00 $434,430.00
Other Income (Expense) -$22,636.00 $17,109.00 $434,430.00
Total Revenue as Reported $2.20M $3.36M $878,971.00

Discussion

No comments yet — be the first to weigh in on SLBT.

Sign in to join the discussion.

Scroll to Top